Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. 1995

E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
Department of Neurology, University of Rochester, School of Medicine and Dentistry, NY.

Differential loss of neurons and terminals occurs in Huntington's disease. Neurons expressing preproenkephalin (PPE) appear to be more vulnerable than neurons expressing preprotachykinin and terminals in the lateral pallidum (containing enkephalin) are more affected than terminals in the medial pallidum (containing substance P). We used in situ hybridization histochemistry and emulsion autoradiography to quantify the number of PPE expressing neurons and the neuronal levels of PPE mRNA in striatum of individuals who died with Huntington's disease and normal controls. We found a grade-related decline in the number of PPE-labeled neurons per field in the striatum of individuals with Huntington's disease compared with controls. Three measures of the neuronal level of PPE mRNA, the mean number of silver grains per PPE neuron, the median number of grains per PPE neuron, and the percentage of PPE neurons with more than 30 grains, were all significantly reduced (41 to 80% of control) in Huntington's disease striatum. The magnitude of the reduction in levels of PPE mRNA per neuron was related to the grade of lesions. These data support the notion that decreased levels of PPE mRNA may account, in part, for the greater loss of enkephalin staining in lateral pallidal terminals compared with substance P staining in medial pallidal terminals. Decreased levels of PPE mRNA may result in clinical symptoms prior to the loss of neurons. The reduction in expression of PPE mRNA suggests that surviving striatal neurons may be affected by the expression of the Huntington's disease gene prior to their imminent cell death.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011498 Protein Precursors Precursors, Protein
D004745 Enkephalins One of the three major families of endogenous opioid peptides. The enkephalins are pentapeptides that are widespread in the central and peripheral nervous systems and in the adrenal medulla. Enkephalin
D005260 Female Females
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006816 Huntington Disease A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4) Huntington Chorea,Juvenile Huntington Disease,Akinetic-Rigid Variant of Huntington Disease,Chorea, Chronic Progressive Hereditary (Huntington),Chronic Progressive Hereditary Chorea (Huntington),Huntington Chronic Progressive Hereditary Chorea,Huntington Disease, Akinetic-Rigid Variant,Huntington Disease, Juvenile,Huntington Disease, Juvenile-Onset,Huntington Disease, Late Onset,Huntington's Chorea,Huntington's Disease,Juvenile-Onset Huntington Disease,Late-Onset Huntington Disease,Progressive Chorea, Chronic Hereditary (Huntington),Progressive Chorea, Hereditary, Chronic (Huntington),Akinetic Rigid Variant of Huntington Disease,Chorea, Huntington,Chorea, Huntington's,Huntington Disease, Akinetic Rigid Variant,Huntington Disease, Juvenile Onset,Huntington Disease, Late-Onset,Juvenile Onset Huntington Disease,Late Onset Huntington Disease
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
December 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience,
E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
January 1988, Brain research,
E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
May 1987, Brain research,
E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
January 1990, Neurology,
E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
January 2011, The Journal of neuroscience : the official journal of the Society for Neuroscience,
E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
April 1991, Journal of neurochemistry,
E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
March 2018, Nature neuroscience,
E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
November 1985, Science (New York, N.Y.),
E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
November 2006, Journal of neuroscience research,
E K Richfield, and K A Maguire-Zeiss, and C Cox, and J Gilmore, and P Voorn
June 2009, Journal of neuroscience research,
Copied contents to your clipboard!